

Maastricht Aging Study

<https://www.neurodegenerationresearch.eu/survey/maastricht-aging-study-2/>

Title of cohort

Maastricht Aging Study

Acronym for cohort

MAAS

Name of Principal Investigator - Title

Dr

Name of Principal Investigator - First name

Martin PJ

Name of Principal Investigator - Last name

van Boxtel

Address of institution -Institution

Maastricht University, Dept. Psychiatry & Neuropsychology

Address of institution - Street address

PO Box 616

Address of institution - City

Maastricht

Address of institution - Postcode

6200MD

Country

Netherlands

Website

<http://maastrichtagingstudy.nl>

Contact email

Funding source

Maastricht University

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias

Q1b. When are studies on the above condition(s) expected to become possible?

Already possible

Q2a. In a single sentence what is the stated aim of the cohort?

Study of normal cognitive aging and the effect of biomedical and psychosocial risk and protective factors

Q2b. What distinguishes this cohort from other population cohorts?

Wide age range (24-81 years at baseline, stratified by age group, general ability and sex)

Q3a. i) Number of publications that involve use of your cohort to date

135

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

See study website

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

**Q4a. Study criteria: what is the age range of participants at recruitment? Age in years
From:**

24

Q4a. Study criteria: what is the age range of participants at recruitment? To:

81

Q4b. Study criteria: what are the inclusion criteria?

Gerontologically healthy

Q4c. Study criteria: what are the exclusion criteria?

no disease of central nervous system

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

1,000-5,000 participants

Q6a. Please describe what measures are used to characterise participants

standard medical and cognitive tests

Q6b. Are there additional measures for participants with a clinical disorder?

at risk participants were additionally screened for cognitive disorders using CAMCOG

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If yes please specify

Q7. What is the study design (select all that apply)?

Prospective cohort| Cross-sectional| Longitudinal

Q8. Are your cases matched by

Q9a. Does your study include a specialised subset of control participants?

No

Q9b. If your study includes a specialised subset of control participants please describe

Q10a. i) Please enter the data collection start date

22/03/1993

Q10a. ii) Please enter the data collection end date

21/07/2007

Q10a. iii) Is data collection for this study

Data analysis ongoing| Closed to new patients

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - intend to apply for funding

Q11. Is data collected

Only through the study

Other please specify here

Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

Yes (participants given permission to be re-contacted via PIs)

Q13a. Please give information on the format and availability of data stored in a database (1)

Data summarised in database

% available

100

Q13a. Please give information on the format and availability of data stored in a database (2)

No

% available

Q13a. Please give information on the format and availability of data stored in a database (3)

No

% available

Q13a. Please give information on the format and availability of data stored in a database (4)

No

% available

Other (please specify)

Yes (not specified)

% available

100

Q13b. Please give information on the format and availability of data held as individual records (1)

Data is held as individual records

% available

100

Q13b. Please give information on the format and availability of data held as individual records (2)

No

% available

Q13b. Please give information on the format and availability of data held as individual records (3)

Data held on computer based records

% available

100

Q13b. Please give information on the format and availability of data held as individual records (4)

No

% available

Please specify language used

Dutch and English

Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource| Access through collaboration with PI only| Access restricted to peer-reviewed work| Completion of research agreement on data use

Q15. What data sharing policy is specified as a condition of use?

Data made publicly available after a specified time point

Q16a. Are tissues/samples/DNA available to other groups?

No

Q16b i) If yes, please describe below:

Q16b. ii) In what form are tissues/samples/DNA supplied?

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Q17. Is information on biological characteristics available to other groups?

Number of Patients
% of total cohort

Types:

Population Cohorts

Member States:

Netherlands

Diseases:

Alzheimer's disease & other dementias

Years:

2016

Database Categories:

N/A

Database Tags:

N/A